Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome

Cancer Letters

Volumn 248, Issue 2, 2007, Pages 219-228

  Kammula, Udai S ^a   Kuntz, Eleanor J ^b   Francone, Todd D ^b   Zeng, Zhaoshi ^b   Shia, Jinru ^b   Landmann, Ron G ^b   Paty, Philip B ^b   Weiser, Martin R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

c Met; Colon cancer; Hepatocyte growth factor; HGF; Metastasis; Outcome; Scatter factor; Survival; Tumor progression; Tumor stage

Indexed keywords

MESSENGER RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH;

ADENOCARCINOMA; AGED; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847326735     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.07.007     Document Type: Article

References (42)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
3. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., and de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350 (2004) 2343-2351
4. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264 (1990) 1444-1450.
5. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
6. Danilkovitch-Miagkova A., and Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109 (2002) 863-867
7. Jeffers M., Rong S., and Woude G.F. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 74 (1996) 505-513
8. Jeffers M., Schmidt L., Nakaigawa N., Webb C.P., Weirich G., Kishida T., Zbar B., and Vande Woude G.F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 11445-11450
9. Fujita S., and Sugano K. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases. Jpn. J. Clin. Oncol. 27 (1997) 378-383
10. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K., and Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 53 (2005) 35-69
11. Hiscox S.E., Hallett M.B., Puntis M.C., Nakamura T., and Jiang W.G. Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers. Cancer Invest. 15 (1997) 513-521
12. Wielenga V.J., van d., Taher V.T.E., Smit L., Beuling E.A., van Krimpen C., Spaargaren M., and Pals S.T. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am. J. Pathol. 157 (2000) 1563-1573
13. Di Renzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., and Giordano S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1 (1995) 147-154
14. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
15. Christensen J.G., Burrows J., and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225 (2005) 1-26
16. Fukuura T., Miki C., Inoue T., Matsumoto K., and Suzuki H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br. J. Cancer 78 (1998) 454-459
17. Takeuchi H., Bilchik A., Saha S., Turner R., Wiese D., Tanaka M., Kuo C., Wang H.J., and Hoon D.S. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9 (2003) 1480-1488
18. Otte J.M., Schmitz F., Kiehne K., Stechele H.U., Banasiewicz T., Krokowicz P., Nakamura T., Folsch U.R., and Herzig K. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61 (2000) 237-246
19. Trusolino L., and Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2 (2002) 289-300
20. Zeng Z., Weiser M.R., D'Alessio M., Grace A., Shia J., and Paty P.B. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin. Exp. Metastasis 21 (2004) 409-417
21. Toi M., Taniguchi T., Ueno T., Asano M., Funata N., Sekiguchi K., Iwanari H., and Tominaga T. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin. Cancer Res. 4 (1998) 659-664
22. Naughton M., Picus J., Zhu X., Catalona W.J., Vollmer R.T., and Humphrey P.A. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J. Urol. 165 (2001) 1325-1328
23. Yoon S.S., Kim S.H., Heffernan N.M., Gonen M., Detwiller K.Y., Jarnagin W.R., D'Angelica M., Blumgart L.H., Tanabe K.K., and DeMatteo R.P. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer metastases. Ann. Surg. Oncol. 13 (2006) 353-362
24. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., and Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16 (1997) 68-73
25. Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., Lubensky I., Neumann H.P., Brauch H., Decker J., Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U., Gerrard B., Dean M., Linehan W.M., and Zbar B. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18 (1999) 2343-2350
26. Francone T.D., Chen T.C., Kunts E.J., Zeng Z., Paty P.B., and Weiser M.R. Mechanisms of MET dysregulation and ligand-dependency in human colorectal cancer. Ann. Surg. Oncol. 13 S (2006) 2
27. Gohda E., Matsunaga T., Kataoka H., Takebe T., and Yamamoto I. Induction of hepatocyte growth factor in human skin fibroblasts by epidermal growth factor, platelet-derived growth factor and fibroblast growth factor. Cytokine 6 (1994) 633-640
28. Tamura M., Arakaki N., Tsubouchi H., Takada H., and Daikuhara Y. Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. J. Biol. Chem. 268 (1993) 8140-8145
29. Jiang W., Hiscox S., Matsumoto K., and Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 29 (1999) 209-248
30. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3 (2003) 453-458
31. Schrag D. Defining optimal treatment for stage II colon cancer: does decision analysis help?. Gastroenterology 117 (1999) 1005-1008
32. Benson III A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., Krzyzanowska M.K., Maroun J., McAllister P., Van Cutsem E., Brouwers M., Charette M., and Haller D.G. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22 (2004) 3408-3419
33. Wickramasinghe D., and Kong-Beltran M. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle 4 (2005) 683-685
34. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
35. Adjei A.A., and Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 23 (2005) 5386-5403
36. Matsumoto K., and Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 94 (2003) 321-327
37. Silvagno F., Follenzi A., Arese M., Prat M., Giraudo E., Gaudino G., Camussi G., Comoglio P.M., and Bussolino F. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1857-1865
38. Cao B., Su Y., Oskarsson M., Zhao P., Kort E.J., Fisher R.J., Wang L.M., and Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98 (2001) 7443-7448
39. Burgess T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., Sun J., Elliott G., Zhang K., Feng X., Jia X.C., Green L., Radinsky R., and Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66 (2006) 1721-1729
40. Abounader R., Ranganathan S., Lal B., Fielding K., Book A., Dietz H., Burger P., and Laterra J. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 91 (1999) 1548-1556
41. Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., and Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (2004) 61-73
42. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.J., Cherrington J.M., and Mendel D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63 (2003) 7345-7355